Aripiprazole lauroxil (Aristada) vs Aripiprazole lauroxil (Aristada Initio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole lauroxil (Aristada)
Marketed by Alkermes plc
NCT01469039 · Phase 3 · completed
The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).
Reported efficacy
The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)
Result source: NCT01469039
Aripiprazole lauroxil (Aristada Initio)
Marketed by Alkermes plc
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole lauroxil (Aristada) | Aripiprazole lauroxil (Aristada Initio) |
|---|---|---|
| PANSS total, change | -21.8 vs -9.8−12 vs placeboNCT014690391 other result
| —Not reported |
| CGI-S, change | -0.5 vs -0.9+0.4 vs placeboNCT016264562 other results
| —Not reported |
| PANSS response | —Not reported | —Not reported |
| PSP, change | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
PANSS total, change
- Aripiprazole lauroxil (Aristada)
- -21.8 vs -9.8−12 vs placeboNCT01469039
1 other result
- -20.9 vs -9.8 NCT01469039
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
CGI-S, change
- Aripiprazole lauroxil (Aristada)
- -0.5 vs -0.9+0.4 vs placeboNCT01626456
2 other results
- -0.3 vs -0.9 NCT01626456
- -0.2 vs -0.9 NCT01626456
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
PANSS response
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
PSP, change
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
Relapse (% of patients)
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Aripiprazole lauroxil (Aristada Initio): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aripiprazole lauroxil (Aristada): 4 of 4 rows · Aripiprazole lauroxil (Aristada Initio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole lauroxil (Aristada) |
|---|---|
| Dropout rate | 35.1%882 mga NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results37.2%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.4% NCT02634320 · Phase 4 · registry result, not featured evidence 12.4%High NCT01895452 · Phase 3 · registry result, not featured evidence 6.2%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —882 mga NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results—441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 7.3%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.9% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 1.5%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 1.9%882 mga NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results1.4%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.1%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 0%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.8% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 0%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 882 mga insomnia 12% (placebo 11.6%) akathisia 11.1% (placebo 4.3%) headache 8.7% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results441 mg akathisia 11.6% (placebo 4.3%) insomnia 9.7% (placebo 11.6%) headache 8.2% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 insomnia 10.1% weight increased 4.6% headache 3% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 headache 6.4% weight increased 6.4% insomnia 2.7% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 anxiety 5.9% NCT02634320 · Phase 4 · registry result, not featured evidence High insomnia 7.1% nasopharyngitis 4% diarrhoea 3.1% NCT01895452 · Phase 3 · registry result, not featured evidence Low diarrhoea 6.2% nasopharyngitis 6.2% toothache 6.2% NCT01895452 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole lauroxil (Aristada)
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole lauroxil (Aristada)'s landscape · Aripiprazole lauroxil (Aristada Initio)'s landscape